[Para valvular leak closure in TAVI].

Fermeture des fuites para-prothétiques des TAVI.

Journal

Annales de cardiologie et d'angeiologie
ISSN: 1768-3181
Titre abrégé: Ann Cardiol Angeiol (Paris)
Pays: France
ID NLM: 0142167

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 18 11 2019
medline: 10 4 2020
entrez: 18 11 2019
Statut: ppublish

Résumé

Literature concerning transcutaneous symptomatic para valvular cardiac leaks closure (PVLC) after trans aortic valve implantation (TAVI) is relatively scarce. Hereby we present 2 clinical cases, one on an Edwards® Sapien 3 valve and the other one on a Medtronic® Evolut R valve. We present also the preliminary results of the 7 PVLC on TAVI included in our prospective FFPP registry during the 2 first years of enrolment (2017-2018), for a total of 158 inclusions for all valves. Seven procedures were performed on 8 leaks, using a majority of vascular plugs (3 Abbott® Amplatzer Vascular Plugs 2 (AVP2), 3 AVP3, 1 AVP4, and 1 muscular Ventricular Septal Defect (VSD) occluder). All procedures were successful without complication. At 1-month follow-up, all patients became asymptomatic. One-year follow-up was already available for 4 patients: 3 of them were symptoms free, and one-who had a second leak not suitable for PVLC-, underwent a « TAVI in TAVI » procedure 2 months after PVLC. This short experience demonstrates the feasibility, the efficacy and the safety of PVLC on TAVI. We expect to be able to offer more in depth information at the end of our prospective ongoing study.

Identifiants

pubmed: 31733689
pii: S0003-3928(19)30110-6
doi: 10.1016/j.ancard.2019.09.027
pii:
doi:

Types de publication

Case Reports Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

453-461

Informations de copyright

Copyright © 2019. Published by Elsevier Masson SAS.

Auteurs

B Gérardin (B)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

D Champagnac (D)

Médipôle Lyon, 69100 Villeurbanne, France.

G Smolka (G)

Medical University of Silesia, 40055 Katowice, Pologne.

H Bouvaist (H)

Centre hospitalo-universitaire de Grenoble, 38700 La-Tronche, France.

R Jakamy (R)

Centre hospitalo universitaire Haut-Lévêque, 33600 Pessac, France.

S Ghostine (S)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

J Naël (J)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

C Garcia (C)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

M Kloeckner (M)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

A Potier (A)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

M A Isorni (MA)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

P Brenot (P)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

S Hascoet (S)

Hôpital Marie-Lannelongue, Le-Plessis-Robinson, 92350 France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH